Predictive value of Tp-e interval, Tp-e/QT, and Tp-e/QTc for disease severity in patients with liver cirrhosis

OBJECTIVE: The cardiovascular system is one of the most affected systems in the liver cirrhosis (LC) process, especially due to the tendency to arrhythmia. Since the data about the relationship between LC and novel electrocardiography (ECG) indexes are lacking, we aimed to investigate the association between LC and Tp-e interval, Tp-e/QT, and Tp-e/QTc ratio. PATIENTS AND METHODS: The study included 100 patients in the study group (56 male, median age 60) and 100 in the control group (52 female, 60 median age) between January 2021 and January 2022. ECG indexes and laboratory findings were analyzed. RESULTS: The patient group had significantly higher heart rate (HR), Tp-e, Tp-e/QT, and Tp-e/QTc compared to the control group (p 20 were 0.877; (95% CI: 0.854-0.900), 0.935; (95% CI: 0.918-0.952), and 0.861; (95% CI: 0.835-0.887); (p < 0.001 for all). CONCLUSIONS: Tp-e, Tp-e/QT, and Tp-e/QTc values were significantly higher in patients with LC. These indexes can be useful for arrhythmia risk stratification and to predict the end-stage of the disease

Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry

Aims The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Non-ST-segment elevation myocardial infarction (NSTEMI) Registry aims to identify international patterns in NSTEMI management in clinical practice and outcomes against the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without ST-segment-elevation. Methods and results Consecutively hospitalised adult NSTEMI patients (n = 3620) were enrolled between 11 March 2019 and 6 March 2021, and individual patient data prospectively collected at 287 centres in 59 participating countries during a two-week enrolment period per centre. The registry collected data relating to baseline characteristics, major outcomes (inhospital death, acute heart failure, cardiogenic shock, bleeding, stroke/transient ischaemic attack, and 30-day mortality) and guideline-recommended NSTEMI care interventions: electrocardiogram pre- or in-hospital, prehospitalization receipt of aspirin, echocardiography, coronary angiography, referral to cardiac rehabilitation, smoking cessation advice, dietary advice, and prescription on discharge of aspirin, P2Y12 inhibition, angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB), beta-blocker, and statin. Conclusion The EORP NSTEMI Registry is an international, prospective registry of care and outcomes of patients treated for NSTEMI, which will provide unique insights into the contemporary management of hospitalised NSTEMI patients, compliance with ESC 2015 NSTEMI Guidelines, and identify potential barriers to optimal management of this common clinical presentation associated with significant morbidity and mortality